{"id":12709,"date":"2019-02-25T11:46:26","date_gmt":"2019-02-25T16:46:26","guid":{"rendered":"https:\/\/medicarereport.org\/?p=12709"},"modified":"2019-02-25T11:46:26","modified_gmt":"2019-02-25T16:46:26","slug":"talk-about-deja-vu-senators-set-to-re-enact-drug-price-hearing-of-60-years-ago","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=12709","title":{"rendered":"Talk About D\u00e9j\u00e0 Vu: Senators Set To Re-Enact Drug Price Hearing Of 60 Years Ago"},"content":{"rendered":"

(By Jay Hancock for Kaiser Health News)<\/p>\n

Kenneth Frazier, CEO of pharma giant Merck, is set to face senators Tuesday who say drug costs are \u201csky-high\u201d and \u201cout of control.\u201d<\/p>\n

But Frazier doesn\u2019t need new talking points. Sixty years ago, a different panel of senators grilled a different Merck boss about the same problem.<\/p>\n

To a striking degree, the subjects likely to surface Tuesday \u2014 high drug prices and profits, limited price transparency, aggressive marketing, alleged patent abuse and mediocre, \u201cme-too\u201d drugs \u2014 are identical to the issues senators investigated decades ago, historical transcripts show.\u00a0 Continue reading article here…<\/a><\/p>\n

Kaiser Health News is a nonprofit national health policy news service that is part of the nonpartisan Henry J. Kaiser Family Foundation.<\/p>\n

\"\"<\/a><\/p>\n

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n","protected":false},"excerpt":{"rendered":"
(By Jay Hancock for Kaiser Health News) Kenneth Frazier, CEO of pharma giant Merck, is set to face senators Tuesday<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[21,10,15],"tags":[],"class_list":["post-12709","post","type-post","status-publish","format-standard","hentry","category-health-care-finance","category-legislative-update","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/12709","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12709"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/12709\/revisions"}],"predecessor-version":[{"id":12710,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/12709\/revisions\/12710"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12709"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12709"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12709"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}